Search results for "vaccination"
showing 10 items of 660 documents
Italian multicentre study found infectious and vaccine-preventable diseases in children adopted from Africa and recommends prompt medical screening
2018
AIM This study evaluated the prevalence of infectious diseases and immunisation status of children adopted from Africa. METHODS We studied 762 African children referred to 11 Italian paediatric centres in 2009-2015. Clinical and laboratory data were retrospectively collected and analysed. RESULTS The median age of the children (60.3% males) was 3 years and 6 months, 52.6% came from Ethiopia and 50.1% had at least one infectious disease. Parasitic infections accounted for the majority of the infectious diseases (409 of 715), and the most common were Giardia lamblia (n = 239), Toxocara canis (n = 65) and skin infections (n = 205), notably Tinea capitis/corporis (n = 134) and Molluscum contagi…
GRAd-COV2, a gorilla adenovirus based candidate vaccine against COVID-19, is safe and immunogenic in young and older adults
2021
AbstractSafe and effective vaccines against coronavirus disease 2019 (COVID-19) are urgently needed to control the ongoing pandemic. Although impressive progress has been made with several COVID-19 vaccines already approved, it is clear that those developed so far cannot meet the global vaccine demand. We have developed a COVID-19 vaccine based on a replication-defective gorilla adenovirus expressing the stabilized pre-fusion SARS-CoV-2 Spike protein, named GRAd-COV2. We aimed to assess the safety and immunogenicity of a single-dose regimen of this vaccine in healthy younger and older adults to select the appropriate dose for each age group. To this purpose, a phase 1, dose-escalation, open…
Coverage or Efficacy: Which Factor is the Most Influential for Reducing Varicella with Routine Childhood Vaccination in Italy?
2014
PIN46 Pharmacoeconomic Evaluation of the Introduction of Universal Varicella Vaccination in Italy
2012
Results after one year of rotavirus universal mass vaccination in Sicily
2015
Background Rotavirus (RV) vaccination is the best strategy to prevent hospitalizations due to rotavirus gastroenteritis (RVGE) and is strongly recommended by international health authority [1]. The Sicilian Health Department introduced rotavirus universal mass vaccination (RUMV) into regional immunizations schedule in 2013 (mean vaccination coverage = 31%). Intussusception is the invagination of one segment of the intestine within a more distal segment and even though the etiology is still unknown, in 1998, a relationship with a tetravalent rotavirus vaccine that was promptly withdrawn was suggested [2]. Post licensure surveillance studies have not confirmed previous findings and no increas…
Intussusception before and after anti-rotavirus vaccination introduction (2009-2013)in Italy
2015
Background Previous studies have identified a possible relationship between anti-rotavirus vaccines and intussusception risk although not confirmed by post licensure studies. In Italy some administrative regions started to introduce rotavirus vaccination in 2013. Monitoring intussusception in pre and post vaccination era will be crucial to ensure safety of the vaccine program. Methods An observational study was carried out to analyze age-specific (0-59 months) Italian trends in intussusception hospitalization rates before (2009–2012) and after (2013) anti-rotavirus vaccine introduction. Results A total of 2,728 hospitalizations for intussusceptions were observed in Italy from 2009 to 2013, …
The Role of Vaccination and Screening in Limiting the Worldwide Disease Burden of Preventable Female Cancers: A Review
2020
Cancer represents one of the most common causes of death worldwide. Among women, breast cancer is the most diagnosed cancer and the principal cause of death due to malignant disease, while cervical cancer ranks fourth for both incidence and mortality. The present review aims to analyze the epidemiology of cervical and breast cancer (incidence, mortality, survival rates, and trends). Moreover, the most important primary and secondary preventive strategies (reduction of risk factors, exposure, vaccination, cancer screening) intended to reduce the future burden of cervical and breast cancer, that should be adopted actively and free of charge, were discussed in accordance to more recent and evi…
mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis
2021
Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous system. A novel coronavirus, namely SARS-CoV-2, has been recently responsible for the highly infectious disease referred as COVID-19, rapidly spreading all over the world. Many vaccines have been developed to control COVID-19 pandemic, including the mRNA vaccines Pfizer/BioNTech (BNT162b2) and Moderna (mRNA1273).1 The vaccination of people with MS (pwMS) has been recommended by several national and international MS societies. However, effectiveness and safety of anti-COVID-19 mRNA vaccines in MS need to be confirmed. The aim of this study was to evaluate the short-term risk of clinical relapses in pwMS in …
A combination vaccine against measles, mumps, rubella and varicella.
2008
A new combination vaccine against measles, mumps, rubella and varicella (MMRV) from GlaxoSmithKline Biologicals has recently been approved in Europe. It combines the components from two well-established, live, attenuated vaccines against measles, mumps and rubella. This review presents a summary of the development of this MMRV vaccine from published clinical studies. Seroconversion rates and antibody titers after the first and second dose are similar to those observed after concomitant administration of the MMR and varicella vaccines. Furthermore, the clinical profile of this combination vaccine, in terms of injection- site and general tolerability, is similar to that of the component vacci…
HAV infection in chronic liver disease: a rationale for vaccination.
2003
We report the conduct and results of a systematic search of the literature to assess whether exposure to HAV could induce a fatal deterioration of liver diseases. We assessed 30 studies and found evidence of progressive decrease of natural immunity against HAV in Italy. HAV vaccine seems as safe in chronic liver diseases than in general population. On the basis of the evidence we recommend that subjects with chronic liver disease should be vaccinated against HAV, especially if younger than 40 years.